Board of Directors

Faheem Hasnain - Chairman

Mr. Hasnain joined the Mirati Board of Directors in February 2019 as Chairman of the Board. He is currently Executive Chairman of Gossamer Bio, Inc. Gossamer Bio has a specific focus on the discovery and development of novel and differentiated therapeutic products to address high unmet needs amongst various targeted patient populations. Prior to joining Gossamer Bio, Mr. Hasnain served as President, CEO and as a Director of Receptos, Inc. from November 2010 to August 2015 when Receptos was acquired by Celgene Corporation. Previously, Mr. Hasnain was the President and Chief Executive Officer and a director of Facet Biotech Corporation, a biology-driven antibody company with a focus in multiple sclerosis and oncology. He held that position from December 2008 until the company’s acquisition by Abbott Laboratories in April 2010.

Previously, Mr. Hasnain was President, Chief Executive Officer and a director of PDL BioPharma, Inc. from October 2008 until Facet Biotech was spun off from PDL BioPharma in December 2008. From October 2004 to September 2008, Mr. Hasnain served at Biogen Idec Inc., a biotechnology company specializing in neurological disorders, autoimmune disorders and cancer, most recently as Executive Vice President in charge of the oncology/rheumatology strategic business unit. Prior to Biogen Idec, Mr. Hasnain held roles with Bristol-Myers Squibb, where he was President of the Oncology Therapeutics Network, and for 14 years at GlaxoSmithKline and its predecessor organizations.

Mr. Hasnain is currently chairman of Vital Therapies, Inc., Tocagen, Inc. and Sente, Inc. and also serves on the board of directors of Kura Oncology, Inc. Prior board experiences include service on the board of directors of Ambit Biosciences Corporation, Seragon Pharmaceuticals, Somaxon Pharmaceuticals, Aragon Pharmaceuticals, and Tercica, Inc. Mr. Hasnain received a B.H.K. and B.Ed. from the University of Windsor Ontario in Canada.

Charles M. Baum, MD, PhD - Director

Dr. Baum was appointed President and Chief Executive Officer and Board Member of Mirati Therapeutics in November 2012. Since then, he has been responsible for moving the company to the United States, listing the company on NASDAQ and establishing its headquarters in San Diego, California. In addition, he has built a world class precision oncology leadership team and transformed Mirati into an company focused on the innovative, targeted development of Mirati’s receptor tyrosine kinase and histone deacetylase inhibitors in various cancers. Prior to joining Mirati he was Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division. Dr. Baum was at Pfizer from 2003 until joining Mirati in 2012, serving in roles of increasing responsibility including as Vice President and Head of Oncology Development and as Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. He was responsible for the development of the oncology portfolio, including Axitinib (Inlyta®), Crizotinib (Xalkori®) and the approval of sunitinib (Sutent®) for the treatment of gastrointestinal stromal tumor (GIST) and renal cell carcinoma. Prior to joining Pfizer, Dr. Baum was responsible for the Phase I-IV development of several oncology compounds at Schering-Plough, including temozolomide (Temodar®) which was approved for the treatment of patients with advanced brain tumors. His career has included academic and hospital positions at Stanford and Emory universities, as well as positions of increasing responsibility within the pharmaceutical industry (Systemix, Searle, Schering-Plough and Pfizer). Dr. Baum currently serves on the board of directors of Array BioPharma. Dr. Baum received his M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine in St. Louis, Missouri and completed his post-graduate training at Stanford University, California. Dr. Baum has received research support from the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts, and holds a number of patents and patent applications.

Dr. Bruce L.A. Carter - Director

Dr. Carter joined Mirati’s Board of Directors in September of 2016. He currently serves on the board of directors of Xencor, Inc. and Enanta Pharmaceuticals, both publicly-held biopharmaceutical companies, as well as Dr. Reddy’s Laboratories, a publicly-held pharmaceutical company based in India. Dr. Carter is an affiliate Professor in the Department of Biotechnology at the University of Washington, Seattle, a position he has held since 1986. Dr. Carter served as executive chairman of the board at Immune Design Corp. from 2009 to 2011, later serving as chairman of the board until 2012 and as a member of the board until 2015. Prior to joining Immune Design, Dr. Carter was the chief executive officer at ZymoGenetics, Inc., one of several managerial roles since joining in 1986 as vice president of research and development. In 1988 Novo Nordisk A/S acquired ZymoGenetics and, in 1994, Dr. Carter was appointed corporate executive vice president and chief scientific officer for Novo Nordisk. In 2000, Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk. As CEO, he was instrumental in transforming ZymoGenetics from the research arm of a European biopharmaceutical company to a company that developed and commercialized Recothrom®. Dr. Carter also held various positions of increasing responsibility at G.D. Searle & Co., Ltd. from 1982 to 1986 and was a Lecturer at Trinity College, University of Dublin from 1975 to 1982. He received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London. Dr. Carter also serves as chairman of the board at the TB Alliance.

Julie M. Cherrington, Ph.D. - Director

Julie M. Cherrington, Ph.D. joined Mirati’s Board of Directors in June 2019. She is an experienced life science executive with extensive insight in bringing drugs into the clinic and through to commercialization. She has been a key contributor to the successful development of multiple FDA-approved products, including SUTENT®, PALLADIA®, VISTIDE®, VIREAD®, and HEPSERA®.

Dr. Cherrington is currently the President and Chief Executive Officer of Arch Oncology, a clinical-stage immuno-oncology company developing novel anti-CD47 mAbs. Previously, she has served as President and Chief Executive Officer at several other oncology companies, including Revitope Oncology, Inc., Zenith Epigenetics, and Pathway Therapeutics, a company advancing targeted kinase inhibitors for the treatment of cancer. In addition, she served as President and Executive Vice President, R&D at Phenomix Corporation. Earlier in her career, Dr. Cherrington was Vice President of Preclinical and Clinical Research at SUGEN, a Pharmacia/Pfizer company. Dr. Cherrington began her career at Gilead Sciences, where she held a range of positions of increasing responsibility. Dr. Cherrington holds a B.S. in biology and an M.S. in microbiology from the University of California, Davis. She earned a Ph.D. in microbiology and immunology from the University of Minnesota and Stanford University. She completed a postdoctoral fellowship at the University of California, San Francisco.

Aaron I. Davis - Director

Mr. Davis has been the Chief Executive Officer of Boxer Capital, the healthcare arm of Tavistock Group, since 2012. Mr. Davis co-founded Boxer Capital in 2005 and, prior to being appointed Chief Executive Officer, served as Portfolio Manager. Since 2016, Mr. Davis has served as the Executive Chairman of CiVi Biopharma, Inc. and as a member of the Board of Directors of Odonate Therapeutics, Inc. (NASDAQ:ODT) and Sojournix, Inc. From 2006 to 2008, he served as a member of the Board of Directors of Kalypsys, Inc. From 2000 to 2004, Mr. Davis worked in the Global Healthcare Investment Banking and Private Equity Group at UBS Warburg, LLC. Mr. Davis received an M.A. degree in biotechnology from Columbia University and a B.B.A. degree in finance from Emory University.

Henry J. Fuchs, MD - Director

Henry J. Fuchs, MD is currently the President of Worldwide Research & Development at BioMarin Pharmaceuticals Inc. (NASDAQ: BMRN), since September 2016 and as the Executive Vice President and Chief Medical Officer from March 2009 to August 2016 and is a seasoned biotech drug development executive. From 2005 to 2008, Dr. Fuchs was Executive Vice President and Chief Medical Officer of Onyx Pharmaceuticals (NASDAQ: ONXX), overseeing expanded development of the kinase inhibitor Nexavar® and other key development programs. From 1996 to 2005, Dr. Fuchs served in multiple roles of increasing responsibility at Ardea Biosciences (NASDAQ: RDEA), first as Vice President, Clinical Affairs, then as President and Chief Operating Officer, and finally as Chief Executive Officer. From 1987 to 1996, Dr. Fuchs held various positions at Genentech where, among other responsibilities, he led the clinical program that resulted in the approval of Pulmozyme®. Dr. Fuchs was also responsible for the Phase III development program that led to the approval of Herceptin® to treat metastatic breast cancer. Dr. Fuchs received an M.D. degree from George Washington University and a B.A. degree in biochemical sciences from Harvard University.

Michael Grey - Director

Mr. Grey currently serves as Executive Chairman of Mirum Pharmaceuticals Inc. and served previously as chief executive officer from the company’s inception in May 2018 to March 2019. Mr. Grey has served as executive chairman of Amplyx Pharmaceuticals, Inc. since January 2017; Reneo Pharmaceuticals, Inc. since December 2017; and Spruce Biosciences, Inc, since April 2017. He has also served as a venture partner at Pappas Ventures since January 2010, served from October 2015 to January 2017 as the president and chief executive officer of Amplyx, and from September 2014 to December 2017 as chairman and chief executive officer of Reneo.  He previously served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., a privately-held biotechnology company before it was acquired by Shire. Between January and September 2009, he served as President and Chief Executive Officer of Auspex Pharmaceuticals, Inc., a private biotechnology company. From January 2005 until its acquisition in August 2008, Mr. Grey was President and Chief Executive Officer of SGX Pharmaceuticals, Inc., a public biotechnology company, where he previously served as President from June 2003 to January 2005 and as Chief Business Officer from April 2001 until June 2003. Prior to joining SGX Pharmaceuticals, Inc., Mr. Grey acted as President, Chief Executive Officer and Board member of Trega Biosciences, Inc., a biotechnology company. From November 1994 to August 1998, Mr. Grey was the President of BioChem Therapeutic, Inc., the pharmaceutical operating division of BioChem Pharma, Inc. During 1994, Mr. Grey served as President and Chief Operating Officer for Ansan, Inc., a pharmaceutical company. From 1974 to 1993, he served in various roles with Glaxo, Inc. and Glaxo Holdings, plc, culminating in the position of Vice President, Corporate Development. Mr. Grey is currently a director of Horizon Pharma, plc. and BioMarin Pharmaceutical, Inc., public pharmaceutical companies.  He received a B.Sc. in chemistry from the University of Nottingham, United Kingdom.

Craig Johnson - Director

Mr. Johnson has served as a director of Mirati since September 2013 and serves on the boards of directors for several life science companies. He is currently a director for Heron Therapeutics Inc. (NASDAQ: HRTX), Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), and La Jolla Pharmaceutical Company (NASDAQ: LJPC). Mr. Johnson also served as a past director of Ardea Biosciences Inc. (NASDAQ: RDEA) from 2008 until its sale to AstraZeneca PLC in 2012. In addition to his board service, Mr. Johnson has served as an advisor to Daisas Medical, LLC since 2012. From 2011 to 2012 he was Chief Financial Officer of PURE Bioscience Inc., and from 2010 to 2011 he was Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics Inc. from 2004 until its sale to Raptor Pharmaceuticals Corp. in 2009, and then as Vice President of a wholly-owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. He held several positions, including Chief Financial Officer and Senior Vice President of Operations, at MitoKor Inc. from 1994 to 2004. Prior to 1994, Mr. Johnson held senior financial positions with several early-stage technology companies, and also practiced as a Certified Public Accountant with Price Waterhouse. Mr. Johnson received his B.B.A. in accounting from the University of Michigan-Dearborn.

Maya Martinez-Davis - Director

Maya Martinez-Davis joined GSK in September 2019 to lead the $20B+ pharmaceuticals and vaccines businesses in the US and Puerto Rico as President, US Pharmaceuticals, effective January 1, 2020.

Previously she served as president of the Biopharma Latin America business for Merck KGaA, Darmstadt, Germany. Maya used her proven expertise driving pharmaceutical business in developed and emerging markets to her role at Merck KGaA, in which she oversaw 14 countries and over 1,000 employees. She guided the region’s strategy for continued business growth by both delivering the company’s planned medical launches and further developing its core healthcare business. Maya led the Regional Leadership Team, where she worked closely with General Managers and heads of regional functions, while also serving as a member of the International Operations Leadership Team.

Maya joined Merck KGaA, Darmstadt, Germany in 2016 as Senior Vice President and Head of Global Oncology for the biopharma business. Aside from leading avelumab (BAVENCIO®) worldwide launch, she supported Merck’s transformation into a recognized global oncology innovator. She also played a critical role in establishing collaborations to strengthen Merck’s presence in the oncology field, including making significant contributions to the alliance with Pfizer. Prior to joining Merck KGaA, Darmstadt, Germany Maya worked at Pfizer as a senior executive for over a decade, where she exercised her vast cross-border, regional and global leadership experience to boost sales growth and market penetration in the areas of Oncology, vaccines and specialty portfolios. In her last role, Maya oversaw the company’s oncology business in the US, managing a large-scale cross-functional team and leading product introductions and launches across multiple tumor types.

Maya holds an undergraduate degree from Saint Louis University and a master’s in business leadership and marketing from the IE Business Institute in Madrid, Spain.

Inspra®, Xalkori®, Inlyta®, and Sutent® are registered trademarks of Pfizer, Inc.
Temodar® is a registered trademark of Merck & Co., Inc.
Nexavar®, Pulmozyme®, and Herceptin® are registered trademarks of Genentech, Inc.